LONDON — Croda International PLC (LSE: CRDA), the U.K.-based specialty chemicals company, saw its shares close at 2,554.00 pence on March 20, 2026, the most recent trading day before the March 23 weekend, marking a 1.43% gain from the previous close of 2,518.00 pence. The stock opened at 2,537.00 pence and traded in a day's range of 2,522.00 to 2,572.00 pence on volume of approximately 1.51 million shares.

Croda International PLC
Croda International PLC

As of the latest available data from major financial platforms including Yahoo Finance, the London Stock Exchange, Investing.com and the company's investor page, no intraday trading occurred on March 23 due to it being a Monday following weekend non-trading hours, with markets closed or pre-open depending on time zones. The London Stock Exchange operates standard hours Monday to Friday, and delayed quotes from March 20 indicate steady momentum following a volatile period earlier in the month. The stock has fluctuated recently, dipping to as low as 2,489.00 pence on March 19 before recovering.

Croda's market capitalization stands around £3.565 billion (approximately $4.5 billion USD at current exchange rates), with 139.35 million shares outstanding. The 52-week range spans a low of 2,426.77 pence (hit August 12, 2025) to a high of 3,312.00 pence (February 24, 2026, around the full-year results release). Year-to-date performance remains negative at about -15.90% from earlier peaks, reflecting broader pressures in the chemicals sector from currency fluctuations, demand softness in industrial segments and past tariff impacts.

The recent uptick aligns with analyst upgrades and positive sentiment post the February 24, 2026, full-year 2025 results announcement. Croda reported resilient performance for the year ended December 31, 2025, with sales up 4.4% to £1.7 billion (6.6% at constant currency), driven by 8% growth in its core Consumer Care and Life Sciences divisions offsetting a 2% decline in Industrial Specialities. Adjusted operating profit rose 7.9% to £295.3 million at constant currency, pushing the margin to 17.4% from 17.2%. Free cash flow reached £162 million in the second half, supported by lower capital expenditures and working capital improvements, with net debt at £524 million and leverage at 1.3x EBITDA.

CEO Steve Foots highlighted early progress on the company's transformation plan, including cost discipline, portfolio streamlining and innovation focus. The board proposed a final dividend of 63 pence, lifting the full-year payout to 111 pence, a slight increase year-over-year, yielding around 4.35% at recent prices.

Looking ahead, Croda outlined an ambitious financial framework through 2028: organic sales growth CAGR of 3-6%, adjusted operating margin exceeding 20% (from 17.4% in 2025), free cash flow-to-sales above 12% and return on invested capital over 10%. For full-year 2026, management guided organic sales growth in the 3-6% range, with adjusted operating profit in line with consensus expectations at constant currency (based on average 2025 rates: USD 1.32, EUR 1.17). First-quarter 2026 sales are expected to match prior-year levels at constant currency due to a tough Q1 2025 comparator (up 9% then).

Challenges persist from external factors. U.S. tariffs in 2025 pressured exports for pharmaceutical and agricultural customers, contributing to subdued demand in some regions. Management noted ongoing tough trading but emphasized resilience through diversification into high-value, sustainable ingredients for beauty, health and crop protection.

Analyst views have turned more constructive. Zacks upgraded the ADR (COIHY) to Buy recently, citing earnings optimism. JPMorgan model updates shifted narratives positively, while Hargreaves Lansdown noted a small beat on profits with outlook in line. Consensus targets and ratings remain supportive, though some caution on macro headwinds like salary inflation (£12 million impact in 2025) and a £10 million depreciation step-up in 2026 from new investments.

Recent company announcements include director/PDMR shareholdings disclosed March 18 and 20, 2026, signaling insider confidence. The Annual Report and Accounts for 2025, released March 16 alongside the Notice of AGM (set for April 22, 2026), reinforce governance and sustainability commitments.

Croda specializes in smart science for high-performance ingredients, serving consumer care (personal care, beauty), life sciences (pharma, health) and industrial specialities (crops, polymers). Its focus on bio-based, sustainable solutions positions it well amid ESG trends, though cyclical exposure in industrials adds volatility.

The stock trades on the FTSE 100 index, though recent performance has lagged broader markets. Beta of around 1.40 indicates higher volatility than the index average. Ex-dividend date for the next payout is April 9, 2026.

Investors monitor upcoming catalysts: first-quarter 2026 sales update (typically late April), half-year results in July and ongoing transformation execution. With margins targeted to rise through efficiency and premium product mix, Croda aims to deliver consistent earnings growth despite sector challenges.

As of March 23, 2026, with no major breaking news overnight, the stock holds steady near recent gains. Traders should check live LSE feeds for any pre-market movements or global influences affecting chemicals stocks.

Croda's strategy emphasizes execution on its plan to grow earnings and returns, positioning the company for potential recovery as demand stabilizes and investments mature.